The Food and Drug Administration announced that Endo has expanded its recall of clonazepam pills due to incorrect labeling of their strength, impacting patient safety.
The agency warned that unintended higher doses of clonazepam could lead to significant sedation, confusion, and dizziness, raising serious health risks for patients.
Endo stated that the expanded recall was triggered by an internal investigation revealing a labeling problem with a third-party vendor, emphasizing patient safety.
The F.D.A. advised that any patients taking clonazepam from the recalled lots should stop usage and consult their healthcare providers immediately.
Collection
[
|
...
]